Adaptimmune Therapeutics (ADAP) Tops Q1 EPS by 19c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/15/2026

1. SPY
2. BAC
3. CRWV
4. NVDA
5. BLK
6. RKLB
7. RXRX
8. NOW
9. CAT
10. NDAQ

Go back to Adaptimmune Therapeutics (ADAP) Tops Q1 EPS by 19c

Adaptimmune Reports First Quarter Financial Results and Business Update

May 12, 2023 7:31 AM EDT

Completed submission of the clinical module (Part 2) of the afami-cel BLA;
afami-cel is targeted to be the first marketed engineered T-cell therapy for a solid tumor

Adaptimmune and GSK agreed terms for transfer of PRAME and NY-ESO target programs; Adaptimmune will receive ~$37 million in upfront and milestone payments

Announced strategic combination with TCR2 to create a preeminent cell therapy company for solid tumors; following closing of the transaction in Q2 2023, cash runway extended into early 2026

Webcast to be held today, May... More